Phase 3 Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who are relatively well and able to carry out daily activities with little or no limitation (as measured by a standard health scale called ECOG, scored 0 or 1)
- People diagnosed with a specific type of oesophageal (food pipe) cancer called squamous cell carcinoma
- People whose cancer has spread to a limited number of sites, specifically no more than 4 distant spread sites in total, no more than 3 spread sites within any single organ, and where each spread site measures no larger than 5cm across
- People who have at least 1 spread site that has been confirmed by a tissue sample (biopsy or similar test)
Who may not be able to join:
- People whose cancer has previously spread widely throughout the body, or whose limited spread is considered to be a result of treatment reducing previously widespread disease (confirm with trial site)
- People who have a hole in or active bleeding from the oesophagus (food pipe)
- People whose cancer continued to grow or spread while being treated with a type of immunotherapy drug called a PD-1 inhibitor
- People whose cancer has come back in an area that was previously treated with radiation therapy
- People who are unable to tolerate chemotherapy or immunotherapy treatments
- People whose lungs have received a level of radiation exposure above a specific safety threshold during prior treatment (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kuaile Zhao, MD, Fudan University
Phone: 86-18017317882
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-free survival difference of PD-1 inhibitor+radiotherapy and PD-1 inhibitor alone
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.